BETAPACE Drug Patent Profile
✉ Email this page to a colleague
When do Betapace patents expire, and what generic alternatives are available?
Betapace is a drug marketed by Legacy Pharma and is included in two NDAs.
The generic ingredient in BETAPACE is sotalol hydrochloride. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the sotalol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Betapace
A generic version of BETAPACE was approved as sotalol hydrochloride by TEVA on May 1st, 2000.
Summary for BETAPACE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 110 |
Clinical Trials: | 5 |
Patent Applications: | 3,311 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for BETAPACE |
What excipients (inactive ingredients) are in BETAPACE? | BETAPACE excipients list |
DailyMed Link: | BETAPACE at DailyMed |
Recent Clinical Trials for BETAPACE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Beijing CTSmed Co. Ltd | Phase 4 |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 |
Medtronic (Shanghai) Management Co. Ltd. | Phase 4 |
Pharmacology for BETAPACE
Drug Class | Antiarrhythmic |
Mechanism of Action | Adrenergic beta-Antagonists |
Physiological Effect | Cardiac Rhythm Alteration |